| bivalirudin versus heparin + GP2b3a inhibitors | |||
| ACUITY (biva alone vs hep+aGP2b3a), 2006 NCT00093158 | bivalirudin alone versus unfractionated heparin or enoxaparin plus a glycoprotein IIb/IIIa inhibitor | in patients with moderate- or high-risk acute coronary syndromes who were undergoing an early invasive strategy. | double blind Follow-up duration: 30 days 17 countries worldwide |
| bivalirudin + GP2b3a inhibitors versus heparin + GP2b3a inhibitors | |||
| ACUITY (biva+aGP2b3a vs hep+aGP2b3a), 2006 NCT00093158 | bivalirudin plus a glycoprotein IIb/IIIa inhibitor
versus unfractionated heparin or enoxaparin plus a glycoprotein IIb/IIIa inhibitor | in patients with moderate- or high-risk acute coronary syndromes who were undergoing an early invasive strategy. | double blind Follow-up duration: 30 days 17 countries worldwide |
in first
in second
-
About
-
Browse pathology
|
treatment
-
Site map
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-
